NASDAQ:DCOY
Decoy Therapeutics Inc.
Decoy Therapeutics Inc. reported net income of −$12.5M in fiscal 2025. Free cash flow was −$5.4M, and the diluted share count rose 20.9%.Summary generated from Decoy Therapeutics Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−338.3%
Debt / equityn/a
Free cash flow−$5.4M
FCF marginn/a
Share count change+20.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 | 0 | n/a | n/a | n/a |
| Operating income | −13 | −32 | −13 | −6 | −13 |
| Net income | −13 | −32 | −13 | −6 | −13 |
| Free cash flow | −10 | n/a | n/a | −5 | −5 |
Recent filings
- S-1Registration statement
Oct 7, 2026 - 8-KEntry into a material agreement
Sep 23, 2026 - 8-KResults of a shareholder vote
Sep 15, 2026 - 4Insider transaction report
Sep 2, 2026 - 4Insider transaction report
Sep 2, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - DEF 14AProxy statement
Aug 4, 2026 - 8-KResults of a shareholder vote
Jul 15, 2026